The efficacy, acceptability, and safety of five atypical antipsychotics in patients with first-episode drug-naïve schizophrenia: a randomized comparative trial

[1] Roussidis A(2013)Reasons and clinical outcomes of antipsychotic treatment switch in outpatients with schizophrenia in real-life clinical settings: the ETOS observational study Ann Gen Psychiatry 12 42-855

[2] Kalkavoura C(2009)Antipsychotic drugs for first-episode schizophrenia: a comparative review CNS Drugs 23 837-1171

[3] Dimelis D(2007)Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder J Clin Psychiatry 68 1163-1223

[4] Theodorou A(2005)Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 1209-2986

[5] Ioannidou I(2007)“Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time J Neurosci. 27 2979-1339

[6] Mellos E(2011)Dynamic regulation of dopamine and serotonin responses to salient stimuli during chronic haloperidol treatment Int J Neuropsychopharmacol. 14 1327-443

[7] Salimi K(2015)Early predictors of ten-year course in first-episode psychosis Psychiatr Serv. 16 438-104

[8] Jarskog LF(2005)Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs Mol Psychiatry 10 79-1313

[9] Lieberman JA(2006)Serum free fatty acids and glucose metabolism, insulin resistance in schizophrenia with chronic antipsychotics Biol Psychiatry 60 1309-13

[10] Dunayevich E(2007)Antipsychotic medications: metabolic and cardiovascular risk J Clin Psychiatry 68 8-41

[1] Roussidis A(2013)Reasons and clinical outcomes of antipsychotic treatment switch in outpatients with schizophrenia in real-life clinical settings: the ETOS observational study Ann Gen Psychiatry 12 42-855

[2] Kalkavoura C(2009)Antipsychotic drugs for first-episode schizophrenia: a comparative review CNS Drugs 23 837-1171

[3] Dimelis D(2007)Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder J Clin Psychiatry 68 1163-1223

[4] Theodorou A(2005)Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 1209-2986

[5] Ioannidou I(2007)“Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time J Neurosci. 27 2979-1339

[6] Mellos E(2011)Dynamic regulation of dopamine and serotonin responses to salient stimuli during chronic haloperidol treatment Int J Neuropsychopharmacol. 14 1327-443

[7] Salimi K(2015)Early predictors of ten-year course in first-episode psychosis Psychiatr Serv. 16 438-104

[8] Jarskog LF(2005)Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs Mol Psychiatry 10 79-1313

[9] Lieberman JA(2006)Serum free fatty acids and glucose metabolism, insulin resistance in schizophrenia with chronic antipsychotics Biol Psychiatry 60 1309-13

[10] Dunayevich E(2007)Antipsychotic medications: metabolic and cardiovascular risk J Clin Psychiatry 68 8-41